BSX bostonscientific.com: מכפיל P/S עתידי

Mass procurement of innovative catheters and stents by global clinics is driving the expansion of Boston Scientific (BSX). The expected price-to-sales ratio listed on GURU.Markets confirms the impact of high demand for high-margin neuromodulation systems, with the metric holding around 2.40. The rise in share prices is based on FDA approvals and the expansion of its international presence, which strengthens the fundamental resilience of the business.

To assess the credit quality of Boston Scientific (BSX), the analyst compares market capitalization with expected sales volumes. Business resilience is driven by demand for cardiovascular surgeries and regulatory approval of new medical devices. By analyzing the projected P/S dynamics, the investor determines the risk of asset overvaluation: an inflated ratio leaves quotes vulnerable to any revenue misses, whereas low values reduce the probability of a collapse.